Advanced Proteome Therapeutics Appoints Dr. David Webb to its Corporate Advisory Board

VANCOUVER, BC / ACCESSWIRE / March 30, 2015 / Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSX VENTURE: APC) (0E8.F) is pleased to announce that its Board of Directors has appointed Dr. David Webb to the Company’s Corporate Advisory Board.

Dr. Webb has been associated with numerous successful initiatives in the pharmaceutical industry and is recognized as a Distinguished Scholar in drug discovery and development. He is currently Adjunct Professor at The Scripps Research Institute (TSRI). At Scripps he has focused on several areas relevant to drug discovery including the detection of circulating tumor cells.

Prior to his current appointment, Dr. Webb held numerous high level positions in the pharmaceutical industry. Dr. Webb joined Celgene-San Diego in September, 2003 as Vice President, Research and led its Research Division in placing six drugs into clinical development, four of which are still in clinical studies (Phases I and II) in the areas of cancer and inflammation/autoimmunity.

Between 1995 and 2003, he held a series of senior management positions in several biotechnology companies where he developed and led drug discovery programs focused on inflammation, asthma, cancer and diabetes. These included Syrrx (Vice President of Drug Discovery, 2001-2003) where he led a team that discovered and developed Alogliptin for type II diabetes; OSI Pharmaceuticals (Corporate Vice President, Drug Discovery 1999-2001) where he was associated with the development of the anticancer drug, Tarceva; and Cadus Pharmaceutical Corporation (Vice President of Research and Chief Scientific Officer, 1995-99). He was also Adjunct Professor of Microbiology and Immunology at New York Medical College during this period.

From 1987 to 1995, Dr. Webb was at Syntex, Inc., where he held the positions of Distinguished Scientist and Director, Institute of Immunology and Biological Sciences and was responsible for all the inflammation and immunology research programs world-wide. He was part of the development team for CelCept, and was a Consulting Professor of Cancer Biology at Stanford University.

Dr. Webb earned a BA, MA in Biology from California State University-Fullerton and his Ph.D. in Microbiology/Immunology at Rutgers, The State University of New Jersey-New Brunswick. He was subsequently appointed a Dernham Junior Fellow of the American Cancer Society, California Division at UCSF.

Dr. Webb has performed exemplary service to the industry. He was Chairman of the Board of Sorrento Therapeutics from 2012-2013 and is also Chairman Emeritus of the Board of BIOCOM (2012), a member of the Executive Committee of the Board of CONNECT, a member of the Board of Directors of the La Jolla Institute of Allergy and Immunology. He currently serves as an advisor/SAB member for several private biotechnology companies. He has also published over 200 papers and abstracts and has been a member of numerous editorial boards and study sections in Immunology.

Dr. Allen (Alexander) Krantz stated that “Dr. Webb has had a long and illustrious career in drug discovery and development and has distinguished himself in numerous areas of therapy, including cancer. He has certainly had the “magic touch” in consistently achieving extraordinary clinical success throughout his career. I am delighted that the Company will have his wise counsel and superb knowledge of immunology and the field of cancer therapeutics impacting our company’s programs.”

About APC

APC has been applying its Foundation Trinity(TM) Technology to proteins targeted for the treatment of cancers. Advanced targeted therapies are designed to attack primarily cancer cells and are expected to dominate the anti-cancer therapeutics’ market in the near future. The Company’s goals are not only to employ therapy targeted for tumor cells, but also to deliver combination therapy in a single, pure therapeutic agent, that can also, in turn, be combined with additional agents to enhance therapies. To achieve this end, it has been the Company’s intention to utilize a unique protein (and related systems), not only as a delivery vehicle to tumor cells, but also as a scaffold upon which to attach each anti-cancer entity to its own specific site on the protein surface — both key to efficient manufacturing and product development. The protein vehicle has emerged as a potential immunotherapeutic as it is implicated in activating the immune system to attack and help clear tumor cells. Immunotherapy is perhaps the most powerful current approach to cancer, and one of great commercial interest to the pharmaceutical industry.

ON BEHALF OF THE BOARD
Alexander (Allen) Krantz
President and Chief Executive Officer

FOR FURTHER INFORMATION PLEASE CONTACT:

Advanced Proteome Therapeutics Corporation
Alexander (Allen) Krantz
President and Chief Executive Officer
Tel: (617) 638-0340
http://www.advancedproteome.com

Scott Young
Investor Relations
Tel: (705) 888-2756

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. The forward-looking statements contained in this news release involve risks and uncertainties, and are subject to change based on various important factors including timely development and acceptance of new products, gaining product approval, successful entry into new markets, changes in financing conditions, and changes in FDA regulations.

SOURCE: Advanced Proteome Therapeutics Corporation 

ReleaseID: 427329